Neal Rosen
Neal Rosen
Professor of Pharmacology, Memorial Sloan-Kettering Cancer Center
mskcc.org üzerinde doğrulanmış e-posta adresine sahip
Başlık
Alıntı yapanlar
Alıntı yapanlar
Yıl
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly, F Rojo, QB She, D Solit, GB Mills, D Smith, H Lane, ...
Cancer research 66 (3), 1500-1508, 2006
25912006
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
PI Poulikakos, C Zhang, G Bollag, KM Shokat, N Rosen
Nature 464 (7287), 427-430, 2010
16222010
Crystal structure of an Hsp90–geldanamycin complex: targeting of a protein chaperone by an antitumor agent
CE Stebbins, AA Russo, C Schneider, N Rosen, FU Hartl, NP Pavletich
Cell 89 (2), 239-250, 1997
15431997
BRAF mutation predicts sensitivity to MEK inhibition
DB Solit, LA Garraway, CA Pratilas, A Sawai, G Getz, A Basso, Q Ye, ...
Nature 439 (7074), 358-362, 2006
13922006
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E)
PI Poulikakos, Y Persaud, M Janakiraman, X Kong, C Ng, G Moriceau, ...
Nature 480 (7377), 387-390, 2011
13252011
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer
BS Carver, C Chapinski, J Wongvipat, H Hieronymus, Y Chen, ...
Cancer cell 19 (5), 575-586, 2011
9782011
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
S Chandarlapaty, A Sawai, M Scaltriti, V Rodrik-Outmezguine, ...
Cancer cell 19 (1), 58-71, 2011
8942011
Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function
AD Basso, DB Solit, G Chiosis, B Giri, P Tsichlis, N Rosen
Journal of Biological Chemistry 277 (42), 39858-39866, 2002
6872002
The tyrosine kinase inhibitor ZD1839 (“Iressa”) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells
MM Moasser, A Basso, SD Averbuch, N Rosen
Cancer research 61 (19), 7184-7188, 2001
6332001
Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway
RC Muise-Helmericks, HL Grimes, A Bellacosa, SE Malstrom, PN Tsichlis, ...
Journal of Biological Chemistry 273 (45), 29864-29872, 1998
6081998
Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress
P Workman, F Burrows, LEN Neckers, N Rosen
Annals of the New York Academy of Sciences 1113 (1), 202-216, 2007
5602007
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity
LH Saal, P Johansson, K Holm, SK Gruvberger-Saal, QB She, M Maurer, ...
Proceedings of the National Academy of Sciences 104 (18), 7564-7569, 2007
5562007
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors
R Bianco, I Shin, CA Ritter, FM Yakes, A Basso, N Rosen, J Tsurutani, ...
Oncogene 22 (18), 2812-2822, 2003
5442003
A peptidomimetic inhibitor of farnesyl: protein transferase blocks the anchorage-dependent and-independent growth of human tumor cell lines
L Sepp-Lorenzino, Z Ma, E Rands, NE Kohl, JB Gibbs, A Oliff, N Rosen
Cancer Research 55 (22), 5302-5309, 1995
5191995
V600EBRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway
CA Pratilas, BS Taylor, Q Ye, A Viale, C Sander, DB Solit, N Rosen
Proceedings of the National Academy of Sciences 106 (11), 4519-4524, 2009
5112009
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts
DB Solit, FF Zheng, M Drobnjak, PN Münster, B Higgins, D Verbel, ...
Clinical cancer research 8 (5), 986-993, 2002
5082002
Tumor adaptation and resistance to RAF inhibitors
P Lito, N Rosen, DB Solit
Nature medicine 19 (11), 1401-1409, 2013
4972013
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
V Serra, M Scaltriti, L Prudkin, PJA Eichhorn, YH Ibrahim, ...
Oncogene 30 (22), 2547-2557, 2011
4912011
Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer
D Yee, S Paik, GS Lebovic, RR Marcus, RE Favoni, KJ Cullen, ...
Molecular Endocrinology 3 (3), 509-517, 1989
4851989
Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90
C Schneider, L Sepp-Lorenzino, E Nimmesgern, O Ouerfelli, ...
Proceedings of the National Academy of Sciences 93 (25), 14536-14541, 1996
4751996
Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.
Makaleler 1–20